je.st
news
Tag: injection
Portable Powder Injection Mixer Designed for Improved Material Handling
2015-07-09 12:31:18| Industrial Newsroom - All News for Today
Hauppauge, NY The newly redesigned Ross Inline Solids/Liquid Injection Manifold (SLIM) Mixer includes an operator-friendly work bench for improved material handling. The SLIM Technology works by pumping liquid from a tank while simultaneously drawing powders and other minor components from a hopper. As the liquid...
Tags: material
designed
improved
handling
Akorn Launches Acetylcysteine Injection
2015-07-08 23:32:37| Biotech - Topix.net
Akorn, Inc. , a leading specialty pharmaceutical company, today announced that it has launched Acetylcysteine Injection 6 g/30 mL in 30 mL single-dose vials. The launch follows an approval of an abbreviated new drug application for the product from the U.S. Food and Drug Administration on March 24, 2015.
Tags: injection
launches
akorn
Charles Ross & Son Co. Introduces Portable Powder Injection Mixer for Improved Material Handling
2015-07-07 07:00:00| Coatings World Breaking News
Tags: son
material
charles
improved
BMW shows future drive technoliges; 2 Series PHEV prototype, direct water injection in 3-cyl. engine, and fuel cell eDrive
2015-07-02 11:57:25| Green Car Congress
Tags: future
series
direct
water
Merck Announces Phase 3 Study of Single-Dose EMEND (fosaprepitant dimeglumine) for Injection Regimen Met Primary Endpoint in Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy
2015-06-29 14:30:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from a Phase 3 study investigating the safety and efficacy of single-dose EMEND (fosaprepitant dimeglumine) for Injection, Mercks substance P/neurokinin (NK-1) receptor antagonist, in combination with other anti-vomiting medicines, for the prevention of chemotherapy-induced nausea and vomiting (CINV) in adult cancer patients receiving moderately emetogenic (vomit-inducing) chemotherapy (MEC). Language: English Contact: MerckMedia:Doris Li, 908-740-1903orAn Phan, 908-255-6325orInvestor:Joseph Romanelli, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Sites : [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] next »